Ubiquitin ligases and cancer

Modulation of Protein Stability in Cancer Therapy

Volumn , Issue , 2009, Pages 1-18

  Burger, Angelika M ^a   Seth, Arun K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; HECT type E3 ligase; RING type E3 ligase; Ubiquitin; Ubiquitin ligase

Indexed keywords

EID: 79951717343     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69147-3_1     Document Type: Chapter

References (92)

1. Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R., Hammond, E. H., Fu, K. K., and Milas, L. 2002. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356.
2. Arndt, K., and Winston, F. 2005. An unexpected role for ubiquitylation of a transcriptional activator. Cell 120:733-737.
3. Attisano, L., and Wrana, J. L. 2002. Signal transduction by the TGF-beta superfamily. Science 296:1646-1647.
4. Azmi, P., and Seth, A. 2005. RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation. Eur J Cancer 41:2549-2560.
5. Baker, S. J. 2007. PTEN enters the nuclear age. Cell 128:25-28.
6. Bohley, P. 1995. The fates of proteins in cells. Naturwissenschaften 82:544-550.
7. Beckmann, J. S., Maurer, F., Delorenz, M., and Falquet, L. 2004. Ubiquitin ligases as cancer genes. Nat Rev Cancer 4: doi:10.1038/nrc1299-c1.
8. Beckmann, J. S., Maurer, F., Delorenz, M., and Falquet, L. 2005. On ubiquitin ligases and cancer. Hum Mutat 25:507-512.
9. Brooks, C. L., and Gu, W. 2006. p53 ubiquitination: Mdm2 and beyond. Mol Cell 21:307-315.
10. Brown, J. P., and Pagano, M. 1997. Mechanism of p53 degradation. Biochim Biophys Acta 1332:1-6
11. Bruggeman, S. W., Valk-Lingbeek, M. E., van der Stoop, P. P., Jacobs, J. J., Kieboom, K., Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S., and van Lohuizen, M. 2005. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19:1438-1443.
12. Buchwald, G., van der Stoop, P., Weichenrieder, O., Perrakis, A., van Lohuizen, M., and Sixma, T. K. 2006. Structure and E3-ligase activity of the ring-ring complex of Polycomb proteins Bmi1 and Ring1b. EMBO J 25:2465-2474.
13. Burger, A., Li, H., Zhang, X. K., Venanzoni, M., Vournakis, J., Papas, T., and Seth, A. 1998. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene 16:327-333.
14. Burger, A. M., and Seth, A. K. 2004. The ubiquitin mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40:2217-2229.
15. Burger, A. M., Gao, Y., Amemiya, Y., Kahn, H. J., Kitching, R., Yang, Y., Sun, P., Narod, S. A., Hanna, W. M., and Seth, A. K. 2005. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 65:10401-10412.
16. Burger, A., Amemiya, Y., Kitching, R., and Seth, A. K. 2006. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 8:689-695.
17. Burger, A. M. 2007. Highlights in experimental therapeutics. Cancer Lett 245:11-21.
18. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. 1997. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230.
19. Ciechanover, A. 2005. Proteolysis: from the lysosome to the ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-86.
20. Chen, C., Sun, X., Guo, P., Dong, X. Y., Sethi, P., Zhou, W., Zhou, A., Petros, J., Frierson Jr, H. F., Vessella, R. L., Atfi, A., Dong, J.-T. 2007a. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26:2386-2394.
21. Chen, C., Zhou, Z., Ross, J. S., Zhou, W., and Dong, J. T. 2007b. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 121:80-87.
22. Chen, C., and Matesic, L. E. 2007. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 26:587-604.
23. Chumsri, S., Matsui, W., and Burger, A. M. 2007. Leukemic stem cell pathways - therapeutic implications. Clin Cancer Res 13:6549-6554.
24. Coscoy, L., and Ganem, D. 2003. PHD domains and E3 ubiquitin ligases: viruses make the connection. Trends Cell Biol 13:7-12.
25. Connor, M. K., Azmi, P. B., Subramaniam, V., Li, H., and Seth, A. 2005. Molecular characterization of Ring-finger protein 11. Mol Cancer Res 3:453-461.
26. d'Azzo, A., Bongiovanni, A., and Nastasi, T. 2005. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic 6:429-441.
27. Dong, Y., Hakimi, M. A., Chen, X., Kumaraswamy, E., Cooch, N. S., Godwin, A. K., and Shiekhattar, R. 2003. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell 12:1087-1099.
28. Dornan, D., Bheddah, S., Newton, K., Ince, W., Frantz, G. D., Dowd, P., Koeppen, H., Dixit, V. M., and French, D. M. 2004. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 64:7226-7230.
29. Duan, L., Miura, Y., Dimri, M., Majumder, B., Dodge, I. L., Reddi, A. L., Ghosh, A., Fernandes, N., Zhou, P., Mullane-Robinson, K., Rao, N., Donoghue, S., Rogers, R. A., Bowtell, D., Naramura, M., Gu, H., Band, V., and Band, H. 2003. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278:28950-28960.
30. Feki, A., Jefford, C. E., Berardi, P., Wu, J. Y., Cartier, L., Krause, K. H., and Irminger-Finger, I. 2005. BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene 24:3726-3736.
31. Fukuchi, M., Fukai, Y., Masuda, N., Miyazaki, T., Nakajima, M., Sohda, M., Manda, R., Tsukada, K., Kato, H., and Kuwano, H. 2002. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 62:7162-7165.
32. Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M. R. 2004. A census of human cancer genes. Nat Rev Cancer 4:177-183.
33. Glickman, M. H., and Ciechanover, A. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428.
34. Goldberg, A. L., Stein, R., and Adams, J. 1995. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2:503-508.
35. Handley-Gaerhart, P. M., Stephen, A. G., Trausch-Azar, J., Ciechanover, A., and Schwartz, A. L. 1994. Human ubiquitin activating enzyme E1, indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs. J Biol Chem 269:33171-33178.
36. Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N., and Nakayama, K. I. 2000. U-box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 276:33111-33120.
37. Hatakeyama, S., and Nakayama, K. I. 2003. U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Comm 302:625-645.
38. Hershko, A., Ciechanover, A., and Varshafsky, A. 2000. The ubiquitin system. Nat Med 10:1073-1074.
39. Hershko, A., Ciechanover, A., Heller, H., Haas, A. L., and Rose, I. A. 1980. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci 77:1783-1786.
40. Hicke, L. 2001. Protein regulation by monoubiquitin. Nat Rev 2:195-201.
41. Horie, K., Urano, T., Ikeda, K., and Inoue, S. 2003. Estorgen-responsive RING-finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 85:101-104.
42. Jacobs, J. J., and van Lohuizen, M. 2002. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602:151-161.
43. Joazeiro, C. A., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T., and Liu, Y. C. 1999. The tyrosine kinase negative regulator cCbl as a RING-type E2-dependent ubiquitin-protein ligase. Science 286:309-312.
44. Joazeiro, C. A. P., and Weissmann, A. M. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549-552.
45. Johnson, G. L., and Lapadat, R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
46. Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H. D., Mayer, T. U., and Jentsch, S. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635-644.
47. Kosarev, P., Mayer, K. F. X., and Hardtke, C. S. 2002. Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome. Genome Biol 3:0016.1-0016.12.
48. Lecker S. H., Goldberg, A. L., and Mitch, W. E. 2006. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-1819.
49. Levkowitz, G., Oved, S., Klapper, L. N., Harari, D., Lavi, S., Sela, M., and Yarden, Y. 2000. c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275:35532-35539.
50. Li, H. X., and Seth, A. 2004. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 23:1801-1808.
51. Li, M., Becnel, L. S., Li, W., Fisher, W. E., Chen, C., and Yao, Q. 2005. Signal transduction in human pancreatic cancer: roles of transforming growth factor a, somatostatin receptors, and other signal intermediates. Arch Immunol Ther Exp 53:381-387.
52. Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N. S., Jackson, K. W., Suri, P., and Wicha, M. S. 2006. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66:6063-6071.
53. Liu, W., Wu, G., Li, W., Lobur, D., and Wan, Y. 2007. Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth actor β-induced growth inhibition. Mol Cell Biol 27:2967-2979.
54. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., and Hirohashi, S. 2007. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98:392-400.
55. Lu, Z., Xu, S., Joazeiro, C., Cobb, M. H., and Hunter, T. 2002. The PHD domain of MEKK1 acts as an E3 Ubiquitin Ligase and mediates ubiquitination ad degradation of ERK1/2. Mol Cell 9:945-956.
56. Lu, Z., and Hunter, T. 2008. MEKK1: dual function as a protein kinase and a ubiquitin protein ligase.2008. In: Protein Degradation, vol. 2, Mayer, J., Ciechanover, A. J., and Rechsteiner, M. (eds.) Wiley, Germany, ISBN: 9783527620210.
57. Ma, Y. M., Boucrot, E., Villén, J., Affar el, B., Gygi, S. P., Göttlinger, H. G., and Kirchhausen, T. 2007. Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation. J Biol Chem 282:9805-9812.
58. Mani, A., and Gelmann, E. P. 2005. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789.
59. McCullough, J., Clague, M. J., and Urbé, S. 2004. AMSH is an endosome-associated ubiquitin isopeptidase. J Cell Biol 166:487-492.
60. Mizoguchi, M., Nutt, C. L., and Louis, D. N. 2004. Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma. Neurogenetics 5:81-82.
61. Mizuno, K., Kitamura, A., and Sasaki, T. 2003. Rabring7, a novel Rab7 target protein with a RING finger motif. Mol Biol Cell 14:3741-3752.
62. Mukherjee, S., Tessema, M., and Wandinger-Ness, A. 2006. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circulation Res 98:743-756.
63. Murata, S., Chiba, T., and Tanaka, K. 2003. CHIP: a quality-control E3 liagse collaborating with molecular chaperones. Int J Biochem Cell Biol 35:572-578.
64. Nalepa, G., and Harper, W. 2003. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 29:49-57.
65. Ohi, M. D., Van der Kooi, C. W., Rosenberg, J. A., Chazin, W. J., and Gould, K. L. 2003. Structural insights into the U-box, a domain associated with multi-ubiquitination. Nat Struct Biol 10:250-255.
66. Ohta, T., and Fukuda, M. 2004. Ubiquitin and breast cancer. Oncogene 23:2079-2088.
67. Onel, K., and Cordon-Cardo, C. 2004. MDM2 and prognosis. Mol Cancer Res 2:1-8.
68. Pagano, M., and Benmaamar, R. 2003. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 4:251-256.
69. Park, K. H., Choi, S. E., Eom, M., and Kang, Y. 2005. Downregulation of the anaphase-promoting complex (APC) 7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res 7:R238-R247.
70. Passmore, L. A., and Barford, D. 2005. Coactivator functions in a stoichiometric complex with anaphasepromoting complex/cyclosome to mediate substrate recognition. EMBO Rep 6:873-878.
71. Pray, T. R., Parlati, F., Huang, J., Wong, B. R., Payan, D. G., Bennett, M. K., Issakani, S. D., Molineaux, S., and Demo, S. D. 2002. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updates 5:249-258.
72. Sahai, E., Garcia-Medina, R., Pouysségur, J., and Vial, E. 2006. Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. Cell Biol 176:35-42.
73. Sakane, A., Hatakeyama, S., and Sasaki, T. 2007. Involvement of Rabring7 in EGF receptor degradation as an E3 ligase. Biochem Biophys Res Comm 357:1058-1064.
74. Scarafia, L. E., Winter, A., and Swinney, D. C. 2000. Quantitative expression analysis of the cellular specificity of HECT-domain ubiquitin E3 ligases. Physiol Genomics 4:147-153.
75. Schmidt, J. J., and Dikic, I. 2006. Ubiquitin and NEDD8: brothers in arms. Sci STKE pe50:1-2.
76. Sentis, S., Le Romancer, M., Bianchin, C., Rostan, M. C., and Corbo, L. 2005. Sumoylation of the estrogen receptor a hinge region by SUMO-E3 ligases PIAS1 and PIAS3 regulates ER a transcriptional activity. Mol Endocrinol 19:2671-2684; doi:10.1210/me.2005-0042.
77. Smalley, K. S. 2003. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104:527-532.
78. Subramaniam, V., Lubovitz, J., Li, H. X., Burger, A., Kitching, R., and Seth, A. 2003. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 89:1538-1544.
79. Tyers, M., and Rottapel, R. 1999. VHL: a very hip ligase. Proc Natl Acad Sci 96:12230-12232.
80. Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y., and Inoue S. 2002. Efp targets 14.3.3s for proteolysis and promotes breast tumour growth. Nature 417:871-875.
81. Wang, H. R., Zhang, Y., Ozdamar, B., Ogunjimi, A. A., Alexandrova, E., Thomsen, G. H., and Wrana, J. L. 2003a. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 302:1775-1779.
82. Wang, Q., Moyret-Lalle, C., Couzon, F., Surbiguet-Clippe, C., Saurin, J. C., Lorca, T., Navarro, C., and Puisieux, A. 2003b. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 22:1486-1490
83. Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, P. P., Jiang, X. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128:129-139.
84. Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat Rev 2:169-178.
85. Wilkinson, K. D. 1997. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11:1245-1256.
86. Xu, W., Marcu, M., Yuan, X., Minnaugh, E., Patterson, C., and Neckers, L. 2002. Chaperonedependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99:12847-12852.
87. Yang, Y., Li, C. C. H., and Weissman, A. M. 2004. Regulating the p53 system through ubiquitination. Oncogene 23:2096-2106.
88. Yarden, Y. 2001. Biology of Her2 and its importance in breast cancer. Oncology 61(Suppl 2):1-13
89. Yoshikawa, K., Ogawa, T., Baer, R., Hemmi, H., Honda, K., Yamauchi, A., Inamoto, T., Ko, K., Yazumi, S., Motoda, H., Kodama, H., Noguchi, S., Gazdar, A. F., Yamaoka, Y., and Takahashi, R. 2000. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 88:28-36.
90. Zhang, Y., Chang, C., Gehling, D. J., Hemmati-Brivanlou, A., and Derynck R. 2001. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 98:974-979.
91. Zheng, N., Wang, P., Jeffrey, P. D., and Pavletich, N. P. 2000. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102:533-539.
92. Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., Conaway, R. C., Conaway, J. W., Harper, J. W., and Pavletich, N. P. 2002. Structure of the Cul1-Rbx1-Skp1-FboxSkp2 SCF ubiquitin ligase complex. Nature 416:703-708.